Document detail
ID

doi:10.1038/s41419-024-06677-8...

Author
Ding, Yamin Huang, Xuan Ji, Tuo Qi, Cong Gao, Xuzhu Wei, Rongbin
Langue
en
Editor

Nature

Category

Life Sciences

Year

2024

listing date

5/8/2024

Keywords
cancer mirnas expression cellular cells ovarian
Metrics

Abstract

Ovarian cancer is one of the common tumors of the female reproductive organs.

It has a high mortality rate, is highly heterogeneous, and early detection and primary prevention are very complex.

Autophagy is a cellular process in which cytoplasmic substrates are targeted for degradation in lysosomes through membrane structures called autophagosomes.

The periodic elimination of damaged, aged, and redundant cellular molecules or organelles through the sequential translation between amino acids and proteins by two biological processes, protein synthesis, and autophagic protein degradation, helps maintain cellular homeostasis.

A growing number of studies have found that autophagy plays a key regulatory role in ovarian cancer.

Interestingly, microRNAs regulate gene expression at the posttranscriptional level and thus can regulate the development and progression of ovarian cancer through the regulation of autophagy in ovarian cancer.

Certain miRNAs have recently emerged as important regulators of autophagy-related gene expression in cancer cells.

Moreover, miRNA analysis studies have now identified a sea of aberrantly expressed miRNAs in ovarian cancer tissues that can affect autophagy in ovarian cancer cells.

In addition, miRNAs in plasma and stromal cells in tumor patients can affect the expression of autophagy-related genes and can be used as biomarkers of ovarian cancer progression.

This review focuses on the potential significance of miRNA-regulated autophagy in the diagnosis and treatment of ovarian cancer.

Ding, Yamin,Huang, Xuan,Ji, Tuo,Qi, Cong,Gao, Xuzhu,Wei, Rongbin, 2024, The emerging roles of miRNA-mediated autophagy in ovarian cancer, Nature

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw